TVAX Biomedical
Olathe, US · Delaware corporation
TVAX Biomedical develops TVAX Immunotherapy, a personalized adoptive T cell therapy for cancer patients that combines a vaccination step using a patient's own cancer cells with activated killer T cell treatment. Its lead candidate, TVI-Brain-1, is in a phase 2b clinical trial for glioblastoma (brain cancer) and has received FDA Fast Track Designation.
Founders & leadership
GW
Gary W. WoodinFounder
TA
Tammie A. WahausExecutive
LL
Lowell L. TilzerExecutive
CE
Catherine E. LucaseyExecutive
Board
BS
Barry S. SkikneBoard director
CB
Charles BurtonBoard director
WG
Wesley GriffittBoard director
Reported raises · per SEC filings
Form D private placements$325.1K disclosed across 1 round · 2016
▶$325.1KraisedJul 2016 · 14 investors · BiotechnologyRule 506(b)
▶$325.1KraisedJul 2016 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Barry S. SkikneDirector
- Charles BurtonDirector
- Tammie A. WahausExecutive Officer
- Lowell L. TilzerExecutive Officer, Director
- Catherine E. LucaseyExecutive Officer, Director
- Wesley GriffittDirector
- Gary W. WoodDirector
- Offering amount
- $500K
- Amount sold
- $325.1K
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 9
by search overlap
Dynavax NASDAQ: DVAX www.dynavax.com12 shared keywordsDynavax is a commercial-stage biopharmaceutical company that develops and commercializes vaccines against infectious diseases using its adjuvant technology. Its products target immunization and infectious disease prevention.
Vaccinex9 shared keywordsVaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer. It also offers a fusion protein and ActivMab antibody discovery technology for incorporating membrane proteins such as GPCRs and ion channels into poxviruses for antibody selection.
Centivax7 shared keywordsCentivax is a biotechnology company developing broad-spectrum vaccines, including a universal influenza vaccine.
CancerVAX7 shared keywordsCancerVax develops cancer therapeutics using lipid nanoparticle technology in partnership with Cytiva. The company is focused on creating nanoparticle-based treatments for cancer patients.
CellVax Therapeutics6 shared keywordsCellVax Therapeutics is a clinical-stage company developing personalized cell-based cancer immunotherapy that converts a patient's own tumor cells into antigen-presenting "Tumor Presenting Cells" to trigger a multi-neoantigen immune response. Its lead product, FK-PC101, targets high-risk prostate cancer patients after prostatectomy, with a platform intended to extend to other solid tumors.
Genvax5 shared keywordsGenvax Technologies develops mRNA and nanoparticle-based vaccines for livestock, focusing on custom, herd-specific formulations that aim to improve speed and precision compared to conventional vaccine platforms. The company serves animal health and food supply sectors.
Bioworld5 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Abivax5 shared keywordsAbivax develops obefazimod, an orally administered small molecule drug candidate with a novel mechanism of action targeting microRNA biology to treat chronic inflammatory diseases including ulcerative colitis and Crohn's disease.
Imvax5 shared keywordsImvax is a clinical-stage biopharmaceutical company developing personalized immunotherapies aimed at treating solid tumors, including glioblastoma. Its platform draws on autologous, cell-based approaches to target cancer.
Companies competing with TVAX Biomedical for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does TVAX Biomedical do?
- TVAX Biomedical develops TVAX Immunotherapy, a personalized adoptive T cell therapy for cancer patients that combines a vaccination step using a patient's own cancer cells with activated killer T cell treatment. Its lead candidate, TVI-Brain-1, is in a phase 2b clinical trial for glioblastoma (brain cancer) and has received FDA Fast Track Designation.
- Who founded TVAX Biomedical?
- TVAX Biomedical was founded by Gary W. Wood.
- How much funding has TVAX Biomedical raised?
- TVAX Biomedical has disclosed $325.1K raised across 1 round.
- Where is TVAX Biomedical headquartered?
- TVAX Biomedical is headquartered in Olathe, US.